CARGO Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
CARGO Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, CARGO Therapeutics, Inc. Common Stock (CRGX) has a cash flow conversion efficiency ratio of -0.326x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-77.38 Million) by net assets ($237.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CARGO Therapeutics, Inc. Common Stock (2021–2024)
Cash flow conversion efficiency of CARGO Therapeutics, Inc. Common Stock from 2021 to 2024. This chart illustrates how CARGO Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CARGO Therapeutics, Inc. Common Stock (CRGX) share price today for real-time trading data and today's change.
CARGO Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
CARGO Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CARGO Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CARGO Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see CRGX company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BRC Inc.
NYSE:BRCC
|
0.080x |
|
Pasifik Gayrimenkul Yatirim Ortakligi AS
IS:PSGYO
|
-0.060x |
|
XRF Scientific Ltd
AU:XRF
|
0.104x |
|
Utah Medical Products Inc
NASDAQ:UTMD
|
0.026x |
|
Asia Sermkij Leasing Public Company Limited
BK:ASK
|
0.203x |
|
Tudor Gold Corp
V:TUD
|
-0.003x |
|
AS Tallinna Vesi
F:A1T
|
0.049x |
|
Mark Dynamics Indonesia Tbk PT
JK:MARK
|
0.094x |
Annual Cash Flow Conversion Efficiency for CARGO Therapeutics, Inc. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of CARGO Therapeutics, Inc. Common Stock from 2021 to 2024. Review CRGX financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $360.23 Million | $-139.74 Million | -0.388x | -93.76% |
| 2023-12-31 | $405.39 Million | $-81.16 Million | -0.200x | -124.27% |
| 2022-12-31 | $-35.24 Million | $-29.07 Million | 0.825x | -97.08% |
| 2021-12-31 | $-175.00K | $-4.94 Million | 28.240x | -- |
About CARGO Therapeutics, Inc. Common Stock
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution design… Read more